secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-09-17T23:59:59+00:00
Accession:  0001104659-25-090834
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports FY2025 net loss $74.4M; sunRIZE topline Dec 2025, FDA streamlines tumor HI trial
--------------------------------------------------------------------------------

- Net loss of $24.4M for Q4 FY2025, $74.4M full year; cash $167.9M as of June 30, 2025 (up from $127.1M).
- Phase 3 sunRIZE (congenital HI) fully enrolled with 62 participants; topline results expected December 2025.
- FDA aligned on streamlined Phase 3 upLIFT (tumor HI) with as few as 16 participants; topline H2 2026.
- Appointed Dr. Sunil Karnawat as Chief Commercial Officer in August 2025 to lead launch strategy.
- R&D expenses $61.5M (FY2025) vs $55.7M; G&A $18.4M vs $14.7M; increases driven by trial and headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/0001104659-25-090834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/tm2526049d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-090834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer